Concurrently, the Nrf2-ARE pathway, a critical regulator of cellular antioxidant defenses, is impaired in AD due to dysregulation of its inhibitor Kelch-like ECH-Associated Protein 1 (Keap1), resulting in reduced nuclear translocation of Nrf2 and decreased expression of vital detoxifying enzymes such as Heme Oxygenase-1 (HO-1) and NAD(P)H Quinone Oxidoreductase 1 (NQO) [110]. Here, NFE2L2 is linked to Alzheimer disease.